Department of Health and Human Services
Public Health Service
12 Sunnen Dr #122
October 6, 1997
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED
LeRoy J. Ballard, President
Nature's Cathedral, Inc.
1995 78th St
Blairstown, IA 52209
Ref. No. STL-98-1
Dear Mr Ballard:
The Food and Drug Administration (FDA) received a complaint regarding injuries sustained by a young woman who experienced an abnormal heart rate with complete heart block, a potentially life-threatening condition. The consumer's symptoms were consistent with an overdose of digitalis-like cardiac glycosides. The young woman experienced this condition after ingesting a regimen of dietary supplements. FDA's investigation determined that the problem was due to the ingredient plantain found in the dietary supplement "Chomper."
FDA's investigation traced this contaminated plantain to your firm. This contamination is associated with plantain that you purchased from Herbarium, Inc. , Kenosha, Wisconsin, and widely distributed throughout the United States between July 1995 and May 1997.
The cut plantain leaves and plantain leaves which you repacked and distributed or distributed as such are adulterated and misbranded under the Federal Food, Drug and Cosmetic Act (the Act) as follows:
- within the meaning of Section 402(a)(1) in that they contain an added poisonous or deleterious substance, namely lanatosides (cardiac glycosides), which may render them injurious to health.
- within the meaning of section 403 (a) (1) in that the labeling is false and misleading because it fails to reveal the material fact that the product contains … lanatosides, e.g. cardiac glycosides, which, if ingested, can cause life-threatening heart reactions.
FDA collected multiple samples of plantain at.various establishments nationwide which had received this mater-ial either directly or indirectly from you. The plantain was being sold as such or used or destined for use in the manufacture of dietary supplements, foods, and other products. FDA analyses of these samples showed that the plant material identified as "plantain" contained lanatosides (cardiac glycosides). The presence of lanatosides support that the plant material contains Digitalis glycosides. Digitalis lanata has been reported to contain these lanatosides. Plantain has not been reported to contain any cardiac glycosides.
FDA also conducted an analysis of a sample of plantain to determine whether the material labeled as plantain actually contained plantain. The analysis found that the characteristic trichomes for plantain were low in concentration in the sample when compared to reference specimens. These analyses indicate that the plantain was contaminated with Digitalis.
As a repacker and distributor, you are responsible for ensuring that foods that you repack or distribute are safe for human consumption. We note that you have voluntarily recalled the adulterated plantain leaves, cut or powdered, that you distributed. However, we are concerned that this type of situation does not occur again.
We request that you notify this office in writing within 15 working days of receipt of this letter of the specific steps you have taken to preclude this violation from occurring in the future. If you continue to distribute foods that are adulterated and misbranded as stated above, FDA may consider initiating regulatory action, such as seizure or injunction.
W. Michael Rogers
This page was posted on August 20, 2006.